HRP20040352B1 - Use of flibanserin in the treatment of sexual disorders - Google Patents

Use of flibanserin in the treatment of sexual disorders

Info

Publication number
HRP20040352B1
HRP20040352B1 HR20040352A HRP20040352A HRP20040352B1 HR P20040352 B1 HRP20040352 B1 HR P20040352B1 HR 20040352 A HR20040352 A HR 20040352A HR P20040352 A HRP20040352 A HR P20040352A HR P20040352 B1 HRP20040352 B1 HR P20040352B1
Authority
HR
Croatia
Prior art keywords
flibanserin
treatment
sexual disorders
medicament
optionally
Prior art date
Application number
HR20040352A
Other languages
English (en)
Croatian (hr)
Inventor
Robert Evans Kenneth
Borsini Franco
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co.Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh & Co.Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co.Kg
Publication of HRP20040352A2 publication Critical patent/HRP20040352A2/hr
Publication of HRP20040352B1 publication Critical patent/HRP20040352B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20040352A 2001-10-20 2004-04-19 Use of flibanserin in the treatment of sexual disorders HRP20040352B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01125020 2001-10-20
PCT/EP2002/011103 WO2003035072A1 (en) 2001-10-20 2002-10-04 Use of flibanserin in the treatment of sexual disorders

Publications (2)

Publication Number Publication Date
HRP20040352A2 HRP20040352A2 (en) 2005-02-28
HRP20040352B1 true HRP20040352B1 (en) 2012-02-29

Family

ID=8179028

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040352A HRP20040352B1 (en) 2001-10-20 2004-04-19 Use of flibanserin in the treatment of sexual disorders

Country Status (31)

Country Link
US (9) US7151103B2 (de)
EP (2) EP1674102A1 (de)
JP (3) JP2005506370A (de)
KR (3) KR20040047931A (de)
CN (4) CN102125557A (de)
AR (2) AR037109A1 (de)
AT (1) ATE327757T1 (de)
AU (1) AU2002333894B2 (de)
BR (1) BR0213358A (de)
CA (1) CA2458067C (de)
CY (1) CY1105082T1 (de)
DE (1) DE60211937T2 (de)
DK (1) DK1446122T5 (de)
EA (1) EA007274B1 (de)
EC (1) ECSP045069A (de)
ES (1) ES2266632T3 (de)
HR (1) HRP20040352B1 (de)
HU (1) HUP0401023A3 (de)
IL (2) IL160389A0 (de)
ME (1) MEP42808A (de)
MX (1) MXPA04003666A (de)
MY (1) MY127290A (de)
NO (1) NO325556B1 (de)
NZ (1) NZ532079A (de)
PL (1) PL208744B1 (de)
PT (1) PT1446122E (de)
RS (1) RS50876B (de)
SI (1) SI1446122T1 (de)
UA (1) UA78974C2 (de)
WO (1) WO2003035072A1 (de)
ZA (1) ZA200401366B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
JP2007516949A (ja) * 2003-07-16 2007-06-28 ファイザー・インク 性機能不全の治療
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
JP4964593B2 (ja) 2003-09-25 2012-07-04 セノメド バイオサイエンシーズ，エルエルシー 神経学的病状の治療用のテトラヒドロインドロン誘導体
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
AU2005235422B2 (en) * 2004-04-22 2011-08-11 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders II
BRPI0511079A (pt) 2004-05-11 2007-12-26 Emotional Brain Bv usos de uma combinação de um inibidor de pde5 e testosterona ou de um seu análogo, e de testosterona ou de um seu análogo, formulação farmacêutica, e, kit de partes
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
EP1789048A1 (de) * 2004-09-03 2007-05-30 Boehringer Ingelheim International GmbH Verfahren zur behandlung von aufmerksamkeitsdefizitstörung mit hyperaktivität
JP2008531714A (ja) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 不安障害の治療用及び／又は予防用の医薬組成物
JP2008538741A (ja) * 2005-03-04 2008-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 鬱病の治療用及び／又は予防用の医薬組成物
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2608249A1 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
US20060264511A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
JP2008540672A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 病状に起因する性的機能不全の治療方法
WO2007006738A2 (en) * 2005-07-12 2007-01-18 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 2 , 3-disubstituted tropanes for the treatment of disorders of sexual desire
CA2617546C (en) 2005-08-03 2014-07-15 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
EP1945214A1 (de) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolon-derivate zur behandlung von prämenstruellen und anderen sexuellen störungen der frau
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
EP1790343A1 (de) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau
EP2233472B1 (de) * 2006-03-28 2014-01-15 Atir Holding S.A. Heterocyclische verbindungen und deren verwendung bei der behandlung von sexualstörungen
EP2021006B1 (de) * 2006-05-09 2015-08-12 Sprout Pharmaceuticals, Inc. Verwendung von flibanserin zur behandlung von postmenopausalen störungen des sexuellen verlangens
JP2009541443A (ja) * 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
EP2043649A2 (de) * 2006-07-14 2009-04-08 Boehringer Ingelheim International GmbH Kombinationen aus flibanserin und koffein, zubereitungsverfahren und ihre verwendung als medikamente
WO2008006838A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
JP5220746B2 (ja) 2006-08-25 2013-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 制御放出システム及びその製造方法
EP1925307A1 (de) 2006-11-03 2008-05-28 Emotional Brain B.V. Verwendung von 3-alpha-androstanediol zur Behandlung sexueller Dysfunktion
ATE524446T1 (de) 2006-12-20 2011-09-15 Boehringer Ingelheim Int Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität
WO2008090742A1 (ja) * 2007-01-23 2008-07-31 National University Corporation Hokkaido University 眼疾患モデル用非ヒト動物
CA2682015A1 (en) * 2007-03-28 2008-10-02 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
CL2008002693A1 (es) * 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
DE102011012712A1 (de) 2011-03-01 2012-09-06 Frank Lehmann-Horn Verwendung von Aldosteron-Rezeptor-Antagonisten zur Behandlung von weiblicher sexueller Dysfunktion
EP2697206B1 (de) 2011-04-10 2019-04-03 Atir Holding S.A. Heterocyclische verbindungen und ihre verwendung bei der behandlung von sexuellen funktionsstörungen
JP2015524474A (ja) * 2012-08-06 2015-08-24 エスワン バイオファーマ インコーポレイテッド 治療レジメン
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
WO2017100324A1 (en) * 2015-12-10 2017-06-15 Repros Therapeutics Inc. Combination therapy for treating female hypoactive sexual desire disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526434A1 (de) * 1991-07-30 1993-02-03 BOEHRINGER INGELHEIM ITALIA S.p.A. Benzimidazolonderivate als 5-HT1A und 5-HT2-Antagonisten
WO2001021593A1 (en) * 1999-09-22 2001-03-29 Boehringer Ingelheim Italia S.P.A. New benzimidazolone derivatives having mixed serotonine and dopamine receptors affinity

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US479739A (en) * 1892-07-26 dimond
US3096248A (en) 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
US3406178A (en) 1964-02-04 1968-10-15 Monsanto Chem Australia Ltd Preparation of 2-substituted benzimidazoles
US3362956A (en) 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US4200641A (en) 1976-12-21 1980-04-29 Janssen Pharmaceutica, N.V. 1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives
DK251079A (da) 1978-06-20 1979-12-21 Synthelabo Fremgangsmaade til fremstilling af phenylpiperazinderivater
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3126703A1 (de) 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
JPS58134033A (ja) 1982-02-02 1983-08-10 Fujisawa Pharmaceut Co Ltd 医薬組成物
IT1176613B (it) 1984-08-14 1987-08-18 Ravizza Spa Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
DE3620643A1 (de) 1985-06-22 1987-01-22 Sandoz Ag Thiazole, ihre herstellung und verwendung
HUT43600A (en) 1985-06-22 1987-11-30 Sandoz Ag Process for production of new thiazole derivatives and medical compound containing those
GB8601160D0 (en) 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
US5036088A (en) 1986-06-09 1991-07-30 Pfizer Inc. Antiallergy and antiinflammatory agents, compositions and use
JPH0784462B2 (ja) 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
US4968508A (en) 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4792452A (en) 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8830312D0 (en) 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
US4954503A (en) 1989-09-11 1990-09-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(1-substituted-4-piperazinyl)-1H-indazoles
WO1992002215A1 (en) 1990-08-09 1992-02-20 Massachusetts Institute Of Technology Method for treating the premenstrual or late luteal phase syndrome
CA2071488C (en) 1990-08-24 1996-05-07 Kazuto Kobayashi Base for film-coating pharmaceuticals and method for preparing same
NZ241613A (en) 1991-02-27 1993-06-25 Janssen Pharmaceutica Nv Highlighting intagliations in tablets
SE9100860D0 (sv) 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
FR2675800A1 (fr) 1991-04-26 1992-10-30 Rhone Poulenc Rorer Sa Derives heterocycliques antiserotonines leur preparation et les medicaments les contenant.
HUT68769A (en) 1991-05-07 1995-07-28 Merck & Co Inc FIBRINOGéN RECEPTOR ANTAGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AS EFFECTIVE SUBSTANCE
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
DE4216364A1 (de) 1991-12-14 1993-11-25 Thomae Gmbh Dr K Neue Pyridylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5225417A (en) 1992-01-21 1993-07-06 G. D. Searle & Co. Opioid agonist compounds
US5492907A (en) 1992-12-09 1996-02-20 The United States Of America As Represented By The Department Of Health & Human Services Antipsychotic composition and method of treatment
JP3204510B2 (ja) 1993-04-05 2001-09-04 コンペティティブ テクノロジーズ，インク． 勃起不全の診断および治療
FR2707294B1 (fr) 1993-07-06 1995-09-29 Pf Medicament Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine.
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
MX9606450A (es) 1994-06-14 1997-03-29 Pfizer Derivados de bencimidazolona.
NZ291223A (en) 1994-08-23 1998-12-23 Smithkline Beecham Plc Medicament containing ibuprofen and codeine, and a carrier containing a hydrogenated vegetable oil as a lubricant
DE69531476T2 (de) 1994-09-12 2004-06-09 Lilly Industries Ltd., Basingstoke Serotonergische Modulatoren
JPH08143476A (ja) 1994-11-18 1996-06-04 Japan Tobacco Inc 薬物放出制御膜及び固形製剤
FR2727682A1 (fr) 1994-12-02 1996-06-07 Pf Medicament Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5883094A (en) 1995-04-24 1999-03-16 Pfizer Inc. Benzimidazolone derivatives with central dopaminergic activity
US5854290A (en) 1995-09-21 1998-12-29 Amy F. T. Arnsten Use of guanfacine in the treatment of behavioral disorders
US6083947A (en) * 1996-01-29 2000-07-04 The Regents Of The University Of California Method for treating sexual dysfunctions
GB9613423D0 (en) 1996-06-26 1996-08-28 Lilly Industries Ltd Pharmaceutical compounds
US5916916A (en) 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
EP0941074B1 (de) 1996-11-06 2004-07-21 Wockhardt Europe Limited System zur verzögerten freisetzung säurelabiler substanzen
JP2001504851A (ja) 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 性的機能不全の治療のためのｎｋ−１受容体拮抗薬の使用
US5859246A (en) 1997-01-30 1999-01-12 Neurogen Corporation 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands
US20040023948A1 (en) 1997-03-24 2004-02-05 Green Richard David Fast-dispersing dosage form containing 5-HT1 agonists
GB9706089D0 (en) 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
BR9810027A (pt) 1997-06-11 2000-09-12 Procter & Gamble Comprimido revestido por pelìcula para melhorada segurança do trato gastrintestinal superior
EP0901787B1 (de) 1997-09-10 2003-05-28 Takeda Chemical Industries, Ltd. Stabilisierte pharmazeutische Zusammensetzung
SE9703375D0 (sv) 1997-09-18 1997-09-18 Astra Ab A new combination
CH692199A8 (fr) 1997-10-09 2002-06-14 Cermol S.A. Composes pyridiques et compositions pharmaceutique
JP3724157B2 (ja) 1997-10-30 2005-12-07 コニカミノルタホールディングス株式会社 映像観察装置
FR2775188B1 (fr) 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
AU4068599A (en) 1998-05-20 1999-12-06 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
EP1077704A4 (de) 1998-05-21 2002-01-30 Lilly Co Eli Kombinationstherapie zur behandlung der depression
US20020151543A1 (en) 1998-05-28 2002-10-17 Sepracor Inc. Compositions and methods employing R (-) fluoxetine and other active ingredients
EP1085869A4 (de) 1998-06-11 2001-10-04 Merck & Co Inc Spiro piperidinderivate als melanocortinrezeptoragonisten
US6068846A (en) 1998-08-05 2000-05-30 Melaleuca, Incorporated Methods and materials for treating depression and mood disorder
EP0982030A3 (de) 1998-08-17 2000-05-10 Pfizer Products Inc. 2,7-substituierte Octahydropyrrolo(1,2-a)pyrazinderivate als 5ht 1a Liganden
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
WO2000028993A1 (en) * 1998-11-19 2000-05-25 Nortran Pharmaceuticals, Inc. Serotonin ligands as pro-erectile compounds
US6680071B1 (en) 1999-03-03 2004-01-20 R. P. Scherer Technologies, Inc. Opioid agonist in a fast dispersing dosage form
WO2000063189A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate
WO2000064441A2 (en) 1999-04-28 2000-11-02 Respiratorius Ab Compound for use as a medicament for treatment of disorders involving bronchocontraction
IT1312310B1 (it) 1999-05-07 2002-04-15 Recordati Ind Chimica E Farma Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US20030055070A1 (en) 1999-07-01 2003-03-20 Wilma Harrison Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction
US6346548B1 (en) 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
DE19961334A1 (de) 1999-12-17 2001-06-21 Roehm Gmbh Spritzgußverfahren für neutrale und säuregruppenhaltige (Meth)acrylat-Copolymere
JP2003523382A (ja) 2000-02-24 2003-08-05 ファルマシア・アンド・アップジョン・カンパニー 新規な薬物の組合せ
KR20030017571A (ko) 2000-06-28 2003-03-03 화이자 프로덕츠 인크. 멜라노코르틴 수용체 리간드
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
US20020052370A1 (en) 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6586435B2 (en) 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
DE60123643T2 (de) 2000-09-19 2007-08-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Benzimidazolonderivate mit affinität zu serotonin- und dopaminrezeptoren
US6521623B1 (en) 2000-09-19 2003-02-18 Boehringer Ingelheim Pharma Kg N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
WO2002024661A2 (en) 2000-09-19 2002-03-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
BR0110450A (pt) 2000-11-22 2005-02-09 Abbott Lab Uso de agonistas receptores d4 de dopamina seletivo para tratamento de disfunção sexual
GB0105893D0 (en) 2001-03-09 2001-04-25 Pfizer Ltd Pharmaceutically active compounds
GB0106446D0 (en) 2001-03-15 2001-05-02 Vernalis Res Ltd Chemical compounds
HUP0303624A3 (en) 2001-03-28 2005-06-28 Pfizer N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad and process for preparation of the compounds
DK1256343T3 (da) 2001-05-11 2006-10-30 Juergen K Dr Beck Flibanserin til behandlingen af extrapyramidale bevægelseslidelser
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
WO2003007949A1 (en) 2001-07-18 2003-01-30 Merck & Co., Inc. Bridged piperidine derivatives as melanocortin receptor agonists
DE60231070D1 (de) 2001-07-30 2009-03-19 Spectrum Pharmaceuticals Inc Arylpiperazin gebundene Purinderivate
HU228666B1 (en) 2001-08-02 2013-05-28 Bidachem Spa Stable polymorph of flibanserin and use thereof for preparing medicaments
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
DE10138273A1 (de) 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung
HUP0202719A3 (en) 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
DE10209982A1 (de) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
US20040048877A1 (en) 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
MXPA04011487A (es) 2002-05-22 2005-02-14 Boehringer Ingelheim Pharma Nuevas composiciones farmaceuticas que contienen flibanserina polimorfo a.
MXPA05000294A (es) 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
US20040132697A1 (en) 2002-11-06 2004-07-08 Pfizer Inc. Treatment of female sexual dysfunction
GB0225908D0 (en) 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
US20040147581A1 (en) 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
US20040193452A1 (en) 2003-01-06 2004-09-30 Laura Berman Method and system for computerized sexual function assessment of female users
WO2004069339A1 (en) 2003-01-29 2004-08-19 Psychogenics Inc. Treatment for attention-deficit hyperactivity disorder
US20050037983A1 (en) 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
JP2007516949A (ja) 2003-07-16 2007-06-28 ファイザー・インク 性機能不全の治療
US20050065158A1 (en) 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
EP1510133A1 (de) * 2003-09-01 2005-03-02 Belovo S.A., Egg Science & Technology Ausgewogene Ölzusammensetzung
NZ545884A (en) 2003-09-11 2010-01-29 Xenoport Inc Treating and/or preventing urinary incontinence using prodrugs of GABA analogs
WO2005044238A1 (en) 2003-11-07 2005-05-19 Ranbaxy Laboratories Limited Modified release solid dosage form of amphetamine salts
US20050239798A1 (en) 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
AU2005235422B2 (en) 2004-04-22 2011-08-11 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders II
US20060014757A1 (en) 2004-07-14 2006-01-19 Boehringer Ingelheim Pharmaceuticals Method for the treatment of anorexia nervosa
US20060025420A1 (en) 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
EP1789048A1 (de) 2004-09-03 2007-05-30 Boehringer Ingelheim International GmbH Verfahren zur behandlung von aufmerksamkeitsdefizitstörung mit hyperaktivität
EP1804778A1 (de) 2004-10-18 2007-07-11 Boehringer Ingelheim International GmbH Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
JP2008531714A (ja) 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 不安障害の治療用及び／又は予防用の医薬組成物
JP2008538741A (ja) 2005-03-04 2008-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 鬱病の治療用及び／又は予防用の医薬組成物
CA2608249A1 (en) 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
US20060258640A1 (en) 2005-05-13 2006-11-16 Boehringer Ingelheim International Gmbh Use of Flibanserin in the treatment of chronic pain
JP2008540672A (ja) 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 病状に起因する性的機能不全の治療方法
US20060264511A1 (en) 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
NZ561375A (en) 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
CA2617546C (en) 2005-08-03 2014-07-15 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
CN101467409A (zh) 2005-08-16 2009-06-24 伟俄内克斯研究公司 包检测
HU227490B1 (en) 2005-08-26 2011-07-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Sustained release pharmaceutical preparation containing carvedilol
US20080275082A1 (en) 2005-09-30 2008-11-06 Jeffrey Brum Pharmaceutical Composition
US20070123540A1 (en) 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
EP1945214A1 (de) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolon-derivate zur behandlung von prämenstruellen und anderen sexuellen störungen der frau
US20070105869A1 (en) 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
KR20140088230A (ko) 2006-01-27 2014-07-09 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
WO2007093624A2 (en) 2006-02-18 2007-08-23 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
WO2007096300A1 (en) 2006-02-20 2007-08-30 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of urinary incontinence
EP1991228A1 (de) 2006-02-28 2008-11-19 Boehringer Ingelheim International GmbH Präventionsbehandlung für herzklappenfehler mit flibanserin
EP2021006B1 (de) 2006-05-09 2015-08-12 Sprout Pharmaceuticals, Inc. Verwendung von flibanserin zur behandlung von postmenopausalen störungen des sexuellen verlangens
JP2009541443A (ja) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
EP2043649A2 (de) 2006-07-14 2009-04-08 Boehringer Ingelheim International GmbH Kombinationen aus flibanserin und koffein, zubereitungsverfahren und ihre verwendung als medikamente
WO2008006838A1 (en) 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
JP5220746B2 (ja) 2006-08-25 2013-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 制御放出システム及びその製造方法
ATE524446T1 (de) 2006-12-20 2011-09-15 Boehringer Ingelheim Int Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität
CA2682015A1 (en) 2007-03-28 2008-10-02 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526434A1 (de) * 1991-07-30 1993-02-03 BOEHRINGER INGELHEIM ITALIA S.p.A. Benzimidazolonderivate als 5-HT1A und 5-HT2-Antagonisten
WO2001021593A1 (en) * 1999-09-22 2001-03-29 Boehringer Ingelheim Italia S.P.A. New benzimidazolone derivatives having mixed serotonine and dopamine receptors affinity

Also Published As

Publication number Publication date
EP1674102A1 (de) 2006-06-28
EA007274B1 (ru) 2006-08-25
ATE327757T1 (de) 2006-06-15
US10307420B2 (en) 2019-06-04
US20180055839A1 (en) 2018-03-01
DE60211937T2 (de) 2006-12-28
US10098876B2 (en) 2018-10-16
MEP42808A (en) 2011-05-10
DK1446122T3 (da) 2006-07-03
CA2458067A1 (en) 2003-05-01
ECSP045069A (es) 2004-05-28
WO2003035072A1 (en) 2003-05-01
MXPA04003666A (es) 2004-07-22
JP2012067134A (ja) 2012-04-05
SI1446122T1 (sl) 2006-10-31
US20170100392A1 (en) 2017-04-13
MY127290A (en) 2006-11-30
AU2002333894B2 (en) 2007-11-01
NZ532079A (en) 2007-03-30
EP1446122A1 (de) 2004-08-18
US20140057923A1 (en) 2014-02-27
AR077480A2 (es) 2011-08-31
AR037109A1 (es) 2004-10-20
IL160389A0 (en) 2004-07-25
IL160389A (en) 2010-05-31
CA2458067C (en) 2009-02-10
KR20110132479A (ko) 2011-12-07
BR0213358A (pt) 2004-10-26
UA78974C2 (en) 2007-05-10
PL208744B1 (pl) 2011-06-30
YU30004A (sh) 2006-08-17
KR101235102B1 (ko) 2013-02-20
US20030104980A1 (en) 2003-06-05
PL367358A1 (en) 2005-02-21
NO20041588L (no) 2004-04-19
RS50876B (sr) 2010-08-31
ES2266632T3 (es) 2007-03-01
US7151103B2 (en) 2006-12-19
CN1571670A (zh) 2005-01-26
US9468639B2 (en) 2016-10-18
CN102125557A (zh) 2011-07-20
US20070072872A1 (en) 2007-03-29
ZA200401366B (en) 2005-01-26
JP2005506370A (ja) 2005-03-03
CY1105082T1 (el) 2010-03-03
US9782403B2 (en) 2017-10-10
EA200400481A1 (ru) 2004-10-28
HUP0401023A3 (en) 2004-10-28
KR20090130196A (ko) 2009-12-18
EP1446122B1 (de) 2006-05-31
US8227471B2 (en) 2012-07-24
CN102058597A (zh) 2011-05-18
HRP20040352A2 (en) 2005-02-28
US20130096137A1 (en) 2013-04-18
HUP0401023A2 (hu) 2004-08-30
KR20040047931A (ko) 2004-06-05
US20150342948A1 (en) 2015-12-03
CN101347431A (zh) 2009-01-21
US20150011563A1 (en) 2015-01-08
DK1446122T5 (da) 2006-08-14
JP2007131631A (ja) 2007-05-31
DE60211937D1 (de) 2006-07-06
NO325556B1 (no) 2008-06-16
US20190000842A1 (en) 2019-01-03
PT1446122E (pt) 2006-08-31

Similar Documents

Publication Publication Date Title
HRP20040352B1 (en) Use of flibanserin in the treatment of sexual disorders
RS51961B (en) APPLICATION OF FLIBANSERINE FOR TREATMENT OF SEXUAL DESIRE DISORDERS IN PREMENOPAUSE
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
CY1106645T1 (el) Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
CY1108105T1 (el) Ιβανδρονικο οξυ για την θεραπευτικη αντιμετωπιση και την προληψη της οστεoπορωσης
RS54398B1 (en) THE USE OF FLIBANSERINE FOR THE TREATMENT OF SEXUAL DESIRE DISORDERS IN POSTMENOPAUSE
EA200701181A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
EE200200107A (et) Kiire algtoimega selektiivse serotoniini tagasihaaramise inhibiitori kasutamine ravimi valmistamiseks, mis on ette nähtud seksuaalse funktsioonihäireravimiseks
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
BR0211063A (pt) Sais de derivados anticonvulsivantes
EP1440689A3 (de) Behandlung von neurotischen Erkrankungen
BR9916887A (pt) Uso de derivados de pirimidina
ECSP045242A (es) Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faríngea
SE0002729D0 (sv) Novel compound form
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
CY1105105T1 (el) Χρηση του διστροντιου αλατος του 2-[ν,ν-δι(καρβοξυμεξυλ) amino]- 3-κυανο-4-καρβοξυμεθυλ-θειοφενο-5-καρβοξυλικου οξεος για τη ληψη φαρμακων που προοριζονται για τη θεραπεια γαστρο-δωδεκαδακτυλικων πονων
WO2003009835A3 (en) Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
IS2214B (is) Meðhöndlun á mígreni með því að gefa inn alfa-lípósýru eða afleiður hennar
RS51316B (sr) Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli
ECSP034632A (es) Uso de compuestos del 6-dimetilaminometil-1-fenil-ciclohexaco sustituido en la terapia de la incontinencia urinaria
HRP20050497B1 (en) Use of levocetirizine for the persistent allergic rhinitis
MXPA01009032A (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso se la produccion de il-12.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20130927

Year of fee payment: 12

PBON Lapse due to non-payment of renewal fee

Effective date: 20141004